← Back to Screener
Travere Therapeutics, Inc. Common Stock (TVTX)
Price$45.04
Value ScoreF
Growth ScoreB
Momentum ScoreA
Favorite Metrics
Price vs S&P 500 (26W)19.92%
Price vs S&P 500 (4W)1.96%
VGM Score60.88
Market Capitalization$4.39B
All Metrics
P/CF (Annual)116.12x
Book Value / Share (Quarterly)$1.07
P/TBV (Annual)1995.76x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)32.28%
Cash Flow / Share (Quarterly)$-0.31
Price vs S&P 500 (YTD)12.54%
Gross Margin (TTM)98.58%
Net Profit Margin (TTM)-4.00%
EPS (TTM)$-0.27
10-Day Avg Trading Volume1.74M
EPS Excl Extra (TTM)$-0.27
Revenue Growth (5Y)19.87%
EPS (Annual)$-0.29
ROI (Annual)-5.99%
Gross Margin (Annual)97.89%
Net Profit Margin (5Y Avg)-86.07%
Cash / Share (Quarterly)$2.86
Revenue Growth QoQ (YoY)55.63%
ROA (Last FY)-4.22%
Revenue Growth TTM (YoY)96.03%
EBITD / Share (TTM)$0.16
ROE (5Y Avg)-266.16%
Operating Margin (TTM)-10.64%
Cash Flow / Share (Annual)$-0.22
P/B Ratio44.44x
P/B Ratio (Quarterly)27.80x
Net Income / Employee (Annual)$-51,400
EV / Revenue (TTM)8.62x
Net Interest Coverage (TTM)-54.64x
ROA (TTM)-3.80%
EV / EBITDA (TTM)317.30x
EPS Incl Extra (Annual)$-0.29
Current Ratio (Annual)2.74x
Quick Ratio (Quarterly)2.81x
3-Month Avg Trading Volume1.97M
52-Week Price Return206.76%
Revenue / Employee (TTM)$1,078,900
Tangible BV / Share (Quarterly)$0.02
P/S Ratio (Annual)8.94x
Asset Turnover (Annual)0.81x
52-Week High$48.61
Operating Margin (5Y Avg)-123.87%
EPS Excl Extra (Annual)$-0.29
CapEx CAGR (5Y)18.81%
Tangible BV CAGR (5Y)-58.03%
26-Week Price Return35.85%
Quick Ratio (Annual)2.52x
13-Week Price Return58.75%
Total Debt / Equity (Annual)2.71x
Current Ratio (Quarterly)3.13x
Enterprise Value$4.62B
Revenue / Share Growth (5Y)5.67%
Asset Turnover (TTM)0.95x
Book Value / Share Growth (5Y)-20.77%
Revenue / Employee (Annual)$987,400
Inventory Turnover (Annual)1.71x
Pretax Margin (Annual)-10.04%
Cash / Share (Annual)$3.55
3-Month Return Std Dev87.97%
Gross Margin (5Y Avg)96.02%
Net Income / Employee (TTM)$-43,100
ROE (Last FY)-22.25%
Net Interest Coverage (Annual)-29.23x
EPS Basic Excl Extra (Annual)$-0.29
P/FCF (TTM)104.93x
Receivables Turnover (TTM)8.81x
Total Debt / Equity (Quarterly)3.16x
EPS Incl Extra (TTM)$-0.27
Receivables Turnover (Annual)9.15x
ROI (TTM)-5.24%
P/S Ratio (TTM)8.18x
Pretax Margin (5Y Avg)-123.33%
Revenue / Share (Annual)$5.50
Tangible BV / Share (Annual)$0.02
Forward P/E57.44x
Price vs S&P 500 (52W)178.56%
Year-to-Date Return23.48%
5-Day Price Return6.19%
EPS Normalized (Annual)$-0.29
ROA (5Y Avg)-27.41%
Net Profit Margin (Annual)-5.21%
Month-to-Date Return12.01%
Cash Flow / Share (TTM)$-4.45
EBITD / Share (Annual)$-0.04
Operating Margin (Annual)-12.80%
LT Debt / Equity (Annual)2.71x
P/CF (TTM)110.76x
ROI (5Y Avg)-39.86%
LT Debt / Equity (Quarterly)3.16x
EPS Basic Excl Extra (TTM)$-0.27
P/TBV (Quarterly)1995.76x
P/B Ratio (Annual)29.77x
Inventory Turnover (TTM)1.48x
Pretax Margin (TTM)-8.36%
Book Value / Share (Annual)$1.26
Price vs S&P 500 (13W)49.00%
Beta1.13x
Revenue / Share (TTM)$5.84
ROE (TTM)-26.79%
52-Week Low$13.88
vGradeF
gGradeB
mGradeA
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.40est. -0.27
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.24
4.24
4.24
4.29
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
TVTXTravere Therapeutics, Inc. Common Stock | F | B | A | $45.04 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Travere Therapeutics is a biopharmaceutical company developing therapies for rare kidney, liver, and metabolic diseases. Its lead candidate, sparsentan, is in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), both rare kidney disorders that can progress to end-stage kidney disease. The company is also advancing pegtibatinase, an investigational enzyme replacement therapy for HCU, a genetic metabolic disorder.